Optum & PAREXEL to Accelerate Drug Development, Reimbursement & Market Access with EHR-Fueled Clinical Research & Hybrid Stud...
January 21 2016 - 9:30AM
Business Wire
Collaboration will focus on advancing drug
development by combining clinical research and real-world
evidence
Optum and PAREXEL International (NASDAQ:PRXL) formed a strategic
alliance to reduce drug development costs associated with
post-approval studies, which are conducted after the approval of a
product to obtain further evidence of its safety or
effectiveness.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160121005795/en/
The strategic alliance combines the strength of Optum’s clinical
data set derived from electronic health records (EHRs), claims data
assets and analytics with PAREXEL’s global, site-based research
experience.
Optum and PAREXEL will offer innovative hybrid studies that
combine existing data from electronic health records (EHRs) and
medical claims with site-based clinical research, which can
accelerate the post-approval collection of clinical evidence for
the life sciences industry. Through these powerful new clinical
studies, Optum and PAREXEL aim to help biopharmaceutical companies
bring new, more effective drugs to market with reduced drug
development costs and increased evidence to support health plan
reimbursement.
“Combining PAREXEL’s clinical research expertise with Optum’s
data resources and analytical capabilities can advance the way new
and innovative drugs are developed, evaluated and brought to market
for the benefit of patients,” said Brian Kelly, president, Optum
Life Sciences. “At Optum, we generate real-world evidence that
helps our clients improve clinical care and, ultimately, make the
health system work better.”
“The pressures to control health care costs mean drug developers
are looking for ways to create efficiencies and cost-savings in
drug development,” said Joshua Schultz, corporate vice president
and worldwide head of PAREXEL Access. “Working with Optum Life
Sciences, PAREXEL will be able to further advance the clinical
research process, helping clients more efficiently develop and
evaluate drugs, reduce the cost of drug development and improve
patient care.”
About Optum
Optum is a leading information and technology-enabled health
services business dedicated to helping make the health system work
better for everyone. With more than 100,000 people worldwide, Optum
delivers intelligent, integrated solutions that help to modernize
the health system and improve overall population health. Optum is
part of UnitedHealth Group (NYSE:UNH). For more information, visit
www.Optum.com.
About PAREXEL
PAREXEL International Corporation is a leading global
biopharmaceutical services organization, providing a broad range of
expertise-based contract research, consulting, medical
communications, and technology solutions and services to the
worldwide pharmaceutical, biotechnology and medical device
industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, medical
education and reimbursement. PAREXEL Informatics provides advanced
technology solutions, including medical imaging, to facilitate the
clinical development process. Headquartered near Boston,
Massachusetts, PAREXEL has offices in 80 locations in 51 countries
around the world, and had approximately 18,620 employees in the
first quarter. For more information about PAREXEL International
visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its affiliates.
All other trademarks are the property of their respective
owners.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
Click here to subscribe to Mobile Alerts for UnitedHealth
Group.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160121005795/en/
OptumChristine Farazi,
952-205-6654christine.farazi@optum.comorPAREXELCristi Barnett,
781-434-4019cristi.barnett@PAREXEL.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Sep 2023 to Sep 2024